| Autor: |
M, Nagabhushan, C M, Miller, T P, Pretlow, J M, Giaconia, N L, Edgehouse, S, Schwartz, H J, Kung, R W, de Vere White, P H, Gumerlock, M I, Resnick, S B, Amini, T G, Pretlow |
| Rok vydání: |
1996 |
| Předmět: |
|
| Zdroj: |
Cancer research. 56(13) |
| ISSN: |
0008-5472 |
| Popis: |
Most patients' prostate cancers respond to androgen deprivation but relapse after periods of several months to years. Only two prostate cancer xenografts, LNCaP and PC-346, have been reported to be responsive to androgen deprivation and to relapse subsequently. Both of these tumors shrink slightly, if at all, and relapse less than 5 weeks after androgen withdrawal. After androgen withdrawal, the human primary prostate cancer xenograft CWR22 regresses markedly, and prostate-specific antigen (PSA) falls up to 3000-fold in the blood of mice. PSA usually returns to normal. In some animals, the tumor relapses and is then designated CWR22R. In these animals, PSA starts to rise approximately 2-7 months, and tumor begins to grow 3-10 months after castration. Animals with CWR22 need to be euthanized because of large tumors 6-12 weeks after the transplantation of CWR22. Androgen withdrawal prolongs life approximately 3-4-fold. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
